Clinical trials located in

Pardubice

Pardubice city is located in Czechia. Currently, 19 clinical trials are being conducted in this city.

Pardubice, located in the Czech Republic, is renowned for its historical and architectural heritage, including the Renaissance-style Pardubice Castle. The city is also famous for the Grand Pardubice Steeplechase, one of the oldest and most challenging horse races in Europe. Pardubice’s unique gingerbread, a traditional delicacy, reflects its rich cultural traditions. The city is situated at the confluence of the Elbe and Chrudimka rivers, offering picturesque landscapes. Additionally, Pardubice is a hub for chemical and engineering industries, balancing its historical charm with modern development.

  • CT-EU-00117215

    Study of a New Drug for Moderate to Severe Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no real effects.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week or so for the first few months. The doctors won’t know which one you’re gettin’ until later. You’ll also need to keep takin’ any anti-inflammatory medicines and doin’ physical therapy exercises as you normally would.

    The main thing the researchers are lookin’ at is whether secukinumab can better improve your physical shoulder symptoms like pain, weakness, stiffness, and such compared to the placebo. They’ll be askin’ you to rate your symptoms at different points durin’ the 24-week study.

    It’s important to know that you can’t increase your anti-inflammatory medicine doses or get steroid injections durin’ the study, but you can take other pain meds like acetaminophen if needed. The study involves some medical tests too, like MRI scans and X-rays of your shoulder.

    So in a nutshell, this trial aims to find out if secukinumab works better than a placebo at relievin’ the symptoms of rotator cuff tendinopathy when combined with standard treatments like physical therapy and anti-inflammatory drugs. If you’re interested, you’d be closely monitored and get either the new medicine or a placebo for free as part of the study.

    BulgariaCzechiaDenmarkFrancePortugalSlovakiaUnited Kingdom
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    BelgiumCzechiaFranceGreeceHungaryNetherlandsPolandSpainUnited Kingdom
  • Testing new treatment for Geographic Atrophy treatment

    This research study pertains to a condition affecting the eyes known as Geographic Atrophy (GA), stemming from the aging process (Age-related Macular Degeneration). The investigation aims to assess the potential efficacy of a new drug (JNJ-81201887), administered through intraocular injection, in improving the aforementioned condition. A comparative analysis will be conducted between individuals receiving the drug and those subjected to a placebo procedure (a simulated intervention lacking an actual drug). Specialized photographs will be taken to quantify any alterations in the condition over an 18-month period. Additionally, observations will be made regarding changes in distant visual acuity, reading ability, and the requirement for aids during these activities over time. Ultimately, the study will examine the impact of the eye condition on daily activities.

    BelgiumCzechiaDenmarkGermanyHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Comparing the effectiveness of two treatments for severe nasal polyps and asthma

    This study is looking at two medications, called Dupilumab and Omalizumab, to see how well they work in people who have severe nose and sinus problems alongside asthma. The main goal is to see if Dupilumab is better at shrinking nasal polyps (small growths in the nose) and improving the sense of smell. Other goals include seeing if Dupilumab can improve symptoms, lung function, and overall health-related quality of life better than Omalizumab. The study also aims to understand how these drugs affect the severity of the disease and asthma control, and their safety. To assess all these, doctors will use various tests, like measuring the size of nasal polyps, testing the ability to smell, and how well one’s lungs are working. Participants in the study will be involved for 38 weeks.

    BelgiumCzechiaDenmarkFinlandFranceGermanyHungaryItalyPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Study on izokibep for treating uveitis

    This medical trial is checking out a new way of treating specific types of eye inflammation using a medicine called izokibep. The types of eye inflammation this trial is focusing on can’t be treated as an infection, and it typically occurs in the middle, back, or throughout the entire eye. Izokibep is a tiny protein that specifically targets and slows down a body substance called interleukin-17A. Our bodies naturally produce this substance, but when it’s involved in inflammation, it can cause problems. Currently, the only way to manage this inflammation is by using high-dose steroid treatments, but this has many negative side effects, making Izokibep a potentially better option.

    AustriaCzechiaFranceGermanyItalySpain
  • Sacituzumab trial for metastatic breast cancer patients

    This study is all about trying a medication named Sacituzumab Govitecan for individuals with a specific kind of breast cancer that has spread beyond the breast (metastatic) and is not affected by certain hormones or proteins. The goal is to see if this medicine can help people live longer by stopping the cancer from growing or spreading. This medicine will be compared with other usual treatments that your doctor may choose, such as paclitaxel or capecitabine. The study also aims to know the percentage of patients who see their cancer shrink as a result of the treatment. Furthermore, the study will also evaluate how the treatment impacts the overall well-being of the patients, through a series of questions related to physical, emotional, and social life.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyPolandPortugalSpainUnited Kingdom
  • Testing new therapy in treating Sudden Sensorineural Hearing Loss

    The testing of a new drug, AC102, is underway in this study for individuals experiencing sudden, unexplained hearing loss, known as Idiopathic Sudden Sensorineural Hearing Loss. The study aims to compare the effectiveness of AC102 with the standard treatment, which involves oral steroid intake. Each patient will receive a single injection of AC102 into the eardrum. The study will evaluate the safety of AC102 and assess the improvement in hearing. After 28 days, the changes in hearing will be measured by testing the understanding of different sound levels.

    AustriaCzechiaGermanyNetherlandsPoland
  • Testing the safety and effectiveness of a new drug in adults with atopic dermatitis

    This trial involves the exploration of a new medication, GSK1070806, for adults afflicted with moderate to severe atopic dermatitis, a skin condition characterized by redness and itching. Over a 16-week period, participants are administered either the new medication or a placebo, a substance devoid of therapeutic properties. This double-blind study ensures that neither the participant nor the doctor is aware of the treatment allocation. Parameters assessed include the medication’s efficacy, safety, drug metabolism within the body, and its impact on the disease. An essential metric is the EASI score, reflecting the severity of the skin condition. Additional assessments encompass the evaluation of itchiness levels, pain intensity, and the disease’s effect on sleep and fatigue. Physicians also document any adverse events, which pertain to unexpected medical incidents related to the drug, and ascertain causality.

    BulgariaCzechiaFranceGermanyGreeceItalyPolandSpain
  • Comparing camizestrant with standard therapy in early breast cancer treatment

    This study, known as CAMBRIA-2, aims to test a medication called Camizestrant for treating early-stage breast cancer that is ER+ and HER2-. It will compare Camizestrant with the standard treatments currently used, which are either Aromatase Inhibitor or Tamoxifen. The study is specifically focused on patients with ER+/HER2- breast cancer who are at high or medium-high risk of their cancer returning. Before they can participate, these patients must have finished all planned cancer treatments, such as surgery or chemotherapy, and currently show no signs of the disease. The main goal of the study is to see whether Camizestrant helps to prevent breast cancer from coming back. This would be measured by looking at the time from when patients join the study to when they first see their breast cancer return, or unfortunately, pass away. The study also aims to see whether Camizestrant improves other measures, such as overall survival and quality of life.

    AustriaBelgiumBulgariaCzechiaFranceGermanyGreeceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Breast cancer treatment study: camizestrant vs. standard therapy

    This study is looking at a new drug called camizestrant for adults with a certain type of early breast cancer (ER+/HER2-). It compares camizestrant with standard endocrine therapies like tamoxifen and aromatase inhibitors in patients who have already received 2–5 years of endocrine therapy. The study’s focus is on preventing cancer recurrence over 60 months. About 4300 participants are involved, and the trial features an open-label design, meaning everyone knows which treatment they are receiving. The main goal is to check how well the camizestrant works in comparison to standard treatments.

    AustriaBelgiumBulgariaCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Long-term safety & effectiveness of rocatinlimab for atopic dermatitis

    This trial is all about studying a medicine called rocatinlimab for grown-ups and teens with a serious skin disease named atopic dermatitis (AD). The main goal is to see if rocatinlimab is safe and can help over a long period. The research will also check how well people tolerate the medication. The focus is on those who previously benefitted from the medicine, showing an improvement on a scoring system that measures itching levels. This trial falls in the third phase, making it crucial towards verifying the effectiveness and monitoring any adverse effects of the drug.

    AustriaCzechiaDenmarkFranceGermanyGreeceHungaryPolandPortugalSlovakiaSpain
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in Czechia:

.